TP Therapeutics pipeline includes potent inhibitors targeting established oncogene drivers, and resistance issues to treatments including secondary resistant mutations, bypass mechanisms, and EMT.  We also work on newly identified disease-driven targets, and targets regulating tumor microenvironment and tumor immunity.  

Our leading project TPX-0005 is now in clinical development (TRIDENT-1, NCT03093116).  More information about TRIDENT-1 is available at ClinicalTrials.gov.  Here is the official title for this clinical trial:  

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Here are two AACR abstracts on TPX-0005:

  1. Ending the endless acquired tyrosine kinase resistance mutations — Design of TPX-0005, a multi-target ALK/ROS1/TRK inhibitor with broad spectrum activity against wild-type and mutants including ALK G1202R, ROS1 G2032R and TRKA G595R
  2. The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors

For more detailed information and discussion, please contact Dr. J. Jean Cui, Chief Scientific Officer, at jean.cui@tptherapeutics.com